Your browser doesn't support javascript.
loading
Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone.
Jalloh, Mohamed F; Wallace, Aaron S; Bunnell, Rebecca E; Carter, Rosalind J; Redd, John T; Nur, Sophia A; Zeebari, Zangin; Ekström, Anna Mia; Nordenstedt, Helena.
Affiliation
  • Jalloh MF; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. Electronic address: mjalloh@cdc.gov.
  • Wallace AS; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
  • Bunnell RE; Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, USA.
  • Carter RJ; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
  • Redd JT; Center for Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, USA.
  • Nur SA; Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, USA.
  • Zeebari Z; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden; Jönköping International Business School, Jönköping, Sweden.
  • Ekström AM; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Nordenstedt H; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Vaccine ; 38(22): 3854-3861, 2020 05 08.
Article in En | MEDLINE | ID: mdl-32291102
ABSTRACT

BACKGROUND:

Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014-2015 outbreak in Sierra Leone.

METHODS:

A cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.

RESULTS:

The largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8-21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach's α = 0.79) and construct validity (single-factor loadings > 0.50).

CONCLUSION:

Perceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccination / Hemorrhagic Fever, Ebola / Ebola Vaccines / Health Resources Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Vaccine Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccination / Hemorrhagic Fever, Ebola / Ebola Vaccines / Health Resources Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Vaccine Year: 2020 Document type: Article
...